To extend these findings, we performed BH3 profiling on KRAS-mutant (G12C and other) NSCLC patient-derived xenograft (PDX) models with or without co-occurring STK11 loss after short-term treatment with trametinib. This evidence concerns the gene KRAS and non-small cell lung carcinoma.